Total Payments
$375,245
2024 Payments
$36,627
Companies
16
Transactions
538
Medicare Patients
1,881
Medicare Billing
$238,542
Payment Breakdown by Category
Other$274,261 (73.1%)
Consulting$48,143 (12.8%)
Travel$38,312 (10.2%)
Food & Beverage$14,411 (3.8%)
Education$118.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $243,601 | 99 | 64.9% |
| Consulting Fee | $48,143 | 18 | 12.8% |
| Travel and Lodging | $38,312 | 127 | 10.2% |
| Honoraria | $15,660 | 14 | 4.2% |
| Food and Beverage | $14,411 | 271 | 3.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,000 | 6 | 3.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000 | 1 | 0.3% |
| Education | $118.99 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $228,158 | 290 | $0 (2024) |
| ABBVIE INC. | $67,776 | 114 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $32,767 | 54 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $24,665 | 44 | $0 (2020) |
| Madrigal Pharmaceuticals | $14,466 | 23 | $0 (2024) |
| Novo Nordisk Inc | $2,713 | 1 | $0 (2023) |
| Eisai Inc. | $1,620 | 1 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,100 | 1 | $0 (2017) |
| Alexion Pharmaceuticals, Inc. | $914.58 | 2 | $0 (2017) |
| Celltrion Healthcare Co., Ltd | $750.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $36,627 | 60 | Gilead Sciences, Inc. ($22,112) |
| 2023 | $27,878 | 32 | Gilead Sciences, Inc. ($25,166) |
| 2022 | $25,359 | 46 | Gilead Sciences, Inc. ($20,081) |
| 2021 | $32,947 | 27 | Gilead Sciences, Inc. ($23,266) |
| 2020 | $25,937 | 32 | Gilead Sciences, Inc. ($19,390) |
| 2019 | $64,679 | 78 | Gilead Sciences, Inc. ($32,411) |
| 2018 | $77,424 | 115 | Gilead Sciences, Inc. ($44,531) |
| 2017 | $84,393 | 148 | Gilead Sciences Inc ($41,201) |
All Payment Transactions
538 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: LIVER DISEASE | ||||||
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.51 | General |
| 12/17/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,410.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/13/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $135.15 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: LIVER DISEASE | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.51 | General |
| 11/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $15.97 | General |
| 11/14/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: LIVER DISEASE | ||||||
| 11/12/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HBV | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Travel and Lodging | In-kind items and services | $422.65 | General |
| Category: HBV | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Food and Beverage | In-kind items and services | $135.32 | General |
| Category: HBV | ||||||
| 11/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: LIVER DISEASE | ||||||
| 10/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.59 | General |
| 10/16/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: LIVER DISEASE | ||||||
| 10/14/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HCV | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $189.26 | General |
| Category: HCV | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $117.81 | General |
| Category: HCV | ||||||
| 10/04/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $29.04 | General |
| Category: LIVER DISEASE | ||||||
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.05 | General |
| 10/03/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.35 | General |
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,935.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $254.00 | General |
| Category: LIVER DISEASE | ||||||
| 09/27/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: LIVER DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 523 | 713 | $238,020 | $59,052 |
| 2022 | 6 | 536 | 703 | $250,350 | $64,382 |
| 2021 | 5 | 410 | 587 | $244,380 | $64,938 |
| 2020 | 6 | 412 | 588 | $237,947 | $50,170 |
Total Patients
1,881
Total Services
2,591
Medicare Billing
$238,542
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 210 | 376 | $166,560 | $44,521 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 69 | $22,350 | $5,560 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $21,460 | $4,058 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 23 | 23 | $15,410 | $3,078 | 20.0% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 182 | 204 | $12,240 | $1,835 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 220 | 370 | $163,920 | $45,590 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $32,140 | $6,672 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 68 | $22,160 | $5,845 | 26.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $16,750 | $3,873 | 23.1% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 156 | 162 | $9,720 | $1,453 | 14.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $5,660 | $949.20 | 16.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 222 | 396 | $177,330 | $49,912 | 28.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 39 | 39 | $26,130 | $6,311 | 24.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 49 | 49 | $25,900 | $5,512 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 28 | 30 | $10,640 | $2,454 | 23.1% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 72 | 73 | $4,380 | $748.98 | 17.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 193 | 350 | $156,240 | $32,273 | 20.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 76 | 76 | $40,080 | $8,616 | 21.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $17,900 | $3,662 | 20.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 45 | 52 | $18,160 | $3,224 | 17.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 32 | 44 | $3,570 | $1,970 | 55.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 40 | 40 | $1,997 | $424.97 | 21.3% |
About Dr. Albert Min, MD
Dr. Albert Min, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396720256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Albert Min, MD has received a total of $375,245 in payments from pharmaceutical and medical device companies, with $36,627 received in 2024. These payments were reported across 538 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($243,601).
As a Medicare-enrolled provider, Min has provided services to 1,881 Medicare beneficiaries, totaling 2,591 services with total Medicare billing of $238,542. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology
- Location New York, NY
- Active Since 12/13/2005
- Last Updated 08/01/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1396720256
Products in Payments
- Epclusa (Drug) $94,966
- Vemlidy (Drug) $91,059
- Mavyret (Drug) $42,499
- OCALIVA (Drug) $20,642
- REZDIFFRA (Drug) $14,344
- MAVYRET (Drug) $12,884
- OCA (Drug) $12,125
- Viekira (Drug) $7,660
- Vosevi (Drug) $6,065
- ZEPATIER (Drug) $5,129
- Lenvima (Drug) $1,620
- Stivarga (Drug) $1,100
- Kanuma (Drug) $914.58
- Inflectra (Biological) $750.00
- RESMETIROM (Drug) $122.02
- ZINPLAVA (Biological) $117.45
- OPDIVO (Biological) $112.69
- REMICADE (Biological) $99.00
- XIFAXAN (Drug) $48.38
- RENFLEXIS (Biological) $40.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554